CSL Limited posts strong first-half financials

Australian biotech company CSL Limited (ASX: CSL), the world's No 2 influenza vaccine provider in sales, today released financial results for the fist half of fiscal year 2022/23, showing that total revenues were up 19% to US$7.184 billion, US$889 million of which is attributable to CSL Vifor.

CSL delivered a net profit after tax of $1.62 billion for the first half of financial year 2023, steady at constant currency (CC) . This included one-off costs associated with the acquisition of Vifor Pharma. Underlying profit (NPATA attributable to CSL shareholders) was $1.82 billion, up 10% at CC.

NPATA earnings per share were $3.772. CSL Guidance reaffirmed guidance: FY 2023 NPATA is anticipated to be in the range of approximately $2.7 billion to $2.8 billion at CC.